Gilead Sciences (GILD) just cleared an important milestone: its once daily bictegravir and lenacapavir combo matched Biktarvy in the Phase 3 ARTISTRY 2 trial, with clean safety data that strengthens ...

Wondering if Gilead Sciences is still a smart buy after its big run, or if the stock has already priced in the good news? Here is a breakdown of whether the current share price really lines up with ...

Gilead Sciences said on Monday its experimental HIV treatment was found to be statistically non-inferior to its top-selling ...

With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...

"Gilead’s HIV ART combo deemed non-inferior in second Phase III trial" was originally created and published by Clinical ...

Gilead Sciences said on Monday its experimental HIV treatment met the main goal and was found to be statistically ...

Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology ...

Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer.

Gilead Sciences (NASDAQ: GILD) has outperformed the market over the past 20 years by 2.66% on an annualized basis producing an average annual return of 11.48%. Currently, Gilead Sciences has a market ...